Approval · Notice of Compliance 3901 · 1997
PREVACID: Notice of Compliance 3901
Issued May 29, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3901
- Date
- May 29, 1997
- Company
- Tap Pharmaceuticals, Inc.Lake Forest, Illinois, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Provides for the following additional indications: 1. maintenance of healed duodenal ulcer 2. maintenance of healed reflux esophagitis 3. long term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrom
- Therapeutic class
- H+, k+-atpase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PREVACID | Not yet assigned | — |
Medicinal ingredients
- LANSOPRAZOLE 15 MG per CAP
- LANSOPRAZOLE 30 MG per CAP